Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for SAB Biotherapeutics, Inc. (SABS : NSDQ)
 
 • Company Description   
SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress Acquisition Corp., is based in SIOUX FALLS, S.D.

Number of Employees: 139

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.94 Daily Weekly Monthly
20 Day Moving Average: 59,646 shares
Shares Outstanding: 42.96 (millions)
Market Capitalization: $83.35 (millions)
Beta: 0.56
52 Week High: $12.90
52 Week Low: $1.61
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -25.67% -18.56%
12 Week -61.12% -57.82%
Year To Date -75.16% -70.46%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2100 EAST 54TH STREET NORTH
-
SIOUX FALLS,SD 57104
USA
ph: 605-679-6980
fax: -
ir@bigcypressaccorp.com http://www.bigcypressaccorp.com
 
 • General Corporate Information   
Officers
Eddie J. Sullivan - Chief Executive Officer
Samuel J. Reich - Executive Chairman
Kipp Erickson - Chief Operating Officer
Russell P. Beyer - Chief Financial Officer
Jeffrey G. Spragens - Director

Peer Information
SAB Biotherapeutics, Inc. (CORR.)
SAB Biotherapeutics, Inc. (RSPI)
SAB Biotherapeutics, Inc. (CGXP)
SAB Biotherapeutics, Inc. (BGEN)
SAB Biotherapeutics, Inc. (GTBP)
SAB Biotherapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 78397T103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 42.96
Most Recent Split Date: (:1)
Beta: 0.56
Market Capitalization: $83.35 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.33 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.02
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -80.61%
ROE
03/31/22 - -134.64
12/31/21 - -174.70
09/30/21 - -
ROA
03/31/22 - -26.70
12/31/21 - -15.92
09/30/21 - -
Current Ratio
03/31/22 - 1.98
12/31/21 - 1.96
09/30/21 - 2.39
Quick Ratio
03/31/22 - 1.98
12/31/21 - 1.96
09/30/21 - 2.39
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -31.35
12/31/21 - -28.16
09/30/21 - -
Book Value
03/31/22 - 0.96
12/31/21 - 0.89
09/30/21 - -2.82
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.09
12/31/21 - 0.10
09/30/21 - -
Debt-to-Capital
03/31/22 - 8.29
12/31/21 - 8.89
09/30/21 - -
 

Powered by Zacks Investment Research ©